Following the FDA’s approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to offer this type of immunotherapy outside of a clinical trial.
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.
New UC San Diego campaign promotes sexual health and has a quick test to prove it. “Good to Go” offers combined testing for HIV and five sexually transmitted diseases, providing some results in as little as 60 seconds and access to free treatment, if needed. Updated clinic opening Dec. 10.
Moores Cancer Center at UC San Diego Health launched the Pancreatic Cancer Prevention and Screening Clinic in an attempt to reduce the number of people who develop the disease and improve survival for those who do. Every day in the U.S., 145 people are diagnosed and every 12 minutes someone dies.
Forty-five faculty members at the University of California San Diego are among the world’s most influential researchers in their fields, according to Clarivate Analytics' list of 2018 "Highly Cited Researchers."
High-tech surgical suites allow doctors to scan patients without either leaving the operating room.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
